What is the recommended dose of Ceftazidime (Ceftazidime) for treating Urinary Tract Infections (UTI)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 11, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Ceftazidime Dosing for Urinary Tract Infections

For urinary tract infections (UTIs), ceftazidime should be dosed at 250 mg intravenously every 12 hours for uncomplicated UTIs and 500 mg intravenously every 8-12 hours for complicated UTIs, with dose adjustments required for renal impairment. 1

Dosing Recommendations Based on UTI Type

Uncomplicated UTIs

  • 250 mg IV every 12 hours 1
  • Duration: Generally 3-5 days after signs and symptoms resolve 2

Complicated UTIs

  • 500 mg IV every 8-12 hours 1
  • Duration: 7-14 days, guided by clinical response 2

Severe/Life-threatening UTIs

  • For severe infections, dosage may be increased to 1-2 grams IV every 8 hours 1
  • In very severe cases, especially with immunocompromised patients, up to 2 grams IV every 8 hours may be used 1

Renal Dosing Adjustments

Ceftazidime is primarily eliminated by glomerular filtration, requiring dose adjustments in renal impairment 1, 3:

Creatinine Clearance (mL/min) Recommended Dose Frequency
>50 Standard dose Standard frequency
31-50 1 gram Every 12 hours
16-30 1 gram Every 24 hours
6-15 500 mg Every 24 hours
<5 500 mg Every 48 hours

Special Populations

Hemodialysis Patients

  • Loading dose: 1 gram
  • Maintenance: 1 gram after each hemodialysis session 1

Peritoneal Dialysis Patients

  • Loading dose: 1 gram
  • Maintenance: 500 mg every 24 hours 1
  • Can be incorporated into dialysis fluid at 250 mg per 2L of dialysis fluid 1

Considerations for Resistant Organisms

For UTIs caused by Carbapenem-Resistant Enterobacterales (CRE), alternative therapies include:

  • Ceftazidime-avibactam 2.5g IV q8h (weak recommendation, very low quality evidence) 4
  • Meropenem-vaborbactam 4g IV q8h (weak recommendation, low quality evidence) 4
  • Imipenem-cilastatin-relebactam 1.25g IV q6h (weak recommendation, low quality evidence) 4
  • Single-dose aminoglycoside for simple cystitis due to CRE 4

Clinical Pearls

  • Obtain cultures before initiating therapy to guide treatment 2
  • Generally continue therapy for 2 days after signs and symptoms of infection have disappeared 1
  • For complicated infections, longer therapy may be required 1
  • Ceftazidime has excellent activity against most gram-negative pathogens including Pseudomonas aeruginosa 5
  • Ceftazidime-avibactam may be considered for complicated UTIs caused by resistant organisms, with a dosage of 2000 mg/500 mg every 8 hours 6

Monitoring

  • Monitor renal function during therapy, especially in patients with pre-existing renal impairment
  • Assess clinical response within 48-72 hours to determine if therapy adjustments are needed
  • Monitor for adverse effects, which are generally mild but may include transient leukopenia or elevated liver enzymes 5

Remember that local resistance patterns should be considered when selecting empiric therapy, and treatment should be adjusted based on culture and sensitivity results when available.

References

Guideline

Urinary Tract Infections Treatment

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

[Pharmacokinetics of ceftazidime in healthy and renal failure subjects].

Presse medicale (Paris, France : 1983), 1988

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Ceftazidime: therapeutic results in various infections and kinetic studies.

The Journal of antimicrobial chemotherapy, 1981

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.